@gltrax1: Your liver could be quietly struggling — and a new GLP-1 cousin just posted big numbers. Efinopegdutide, an investigational once-weekly GLP-1 + glucagon drug from Merck, resolved MASH — a serious form of fatty liver disease — in 63% of people at the 7 mg dose vs 13% on placebo, in a 52-week Phase 2b trial of 386 adults. Results were presented Nov 9 at The Liver Meeting and published in The Lancet. About 1 in 20 people worldwide may have MASH, and it often has no symptoms. It's NOT approved yet — it holds FDA Fast Track status, and the most common side effects were nausea and vomiting. This is research news, not medical advice — if liver health is on your mind, talk to your doctor about screening and options. Did you know GLP-1s were being tested for liver disease? #GLP1 #MASH #LiverHealth #GLTrax

GLTrax
GLTrax
Open In TikTok:
Region: US
Tuesday 10 November 2026 21:57:08 GMT
0
0
0
0

Music

Download

Comments

There are no more comments for this video.
To see more videos from user @gltrax1, please go to the Tikwm homepage.

Other Videos


About